Crossmark

Brief Communication: Factors associated with willingness to use long-acting injectable Cabotegravir for HIV pre-exposure prophylaxis (PrEP) among female undergraduate students at a Ugandan university

Crossref DOI link: https://doi.org/10.1186/s12981-024-00686-5

Published Online: 2024-12-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Atuhaire, Bridget

Muteebwa, Laban

Nabunya, Racheal

Muhindo, Richard

Ngabirano, Tom Denis

Osingada, Charles Peter

Muwanguzi, Patience A.
Funding

Funding for this research was provided by:

National Institutes of Health (D43TW010037)

European and Developing Countries Clinical Trials Partnership (CSA2018HS-2518)
License Information

Text and Data Mining valid from 2024-12-20

Version of Record valid from 2024-12-20
More Information

Article History

Received: 19 July 2024

Accepted: 3 December 2024

First Online: 20 December 2024

Declarations

:

: This study protocol and tools were approved by the Makerere University School of Health Sciences Research Ethics Committee (MAKSHSREC-2024-665). The principal of the College of Health Sciences and the Department of Nursing at Makerere University also granted permission to conduct the study. Participants provided electronic consent before participating in the study. Participation was voluntary, without consequences for those who chose not to participate. All methods followed relevant guidelines and regulations.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below